Kymera Therapeutics (KYMR) Misses Q3 EPS by 26c

Kymera Therapeutics (NASDAQ: KYMR) reported Q3 EPS of ($0.90), $0.26 worse than the analyst estimate of ($0.64). Revenue for the quarter came in at $4.73 million versus the consensus estimate of $15.97 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.

You May Also Be Interested In

• John Wiley & Sons, Inc. (WLY) Tops Q1 EPS by 4c ; Offers Guidance
• Planet Labs (PL) Tops Q2 EPS by 4c, Offers Guidance
• Ambarella (AMBA) Tops Q2 EPS by 1c; offers guidance